CLT 001
Alternative Names: HP-HSCLatest Information Update: 26 Jun 2015
Price :
$50 *
At a glance
- Originator Cellerant Therapeutics
- Class Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Sickle cell anaemia
Most Recent Events
- 27 Feb 2007 Phase-II clinical trials in Cancer in USA (Parenteral)
- 04 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) Bacterial Infections pharmacodynamics section
- 30 Aug 2005 Preclinical trials in Autoimmune disorders in USA (unspecified route)